Ivabradine Synthon

Ivabradine, the active ingredient in Ivabradine Synthon, is an If channel inhibitor presented as an oral dosage form for oral use. It reduces heart rate and is indicated for the treatment of stable angina pectoris and chronic heart failure in appropriate patients.

GNH USA supplies Ivabradine Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Ivabradine is an If channel inhibitor used in cardiovascular conditions that require heart‑rate reduction.

- Stable angina pectoris: lowers heart rate to reduce frequency and severity of chest pain episodes. - Chronic heart failure (NYHA class II‑III): improves exercise tolerance and may decrease hospitalization risk. - Patients intolerant to beta‑blockers: provides heart‑rate control without affecting myocardial contractility.

Ivabradine may cause a range of adverse reactions, which are categorised by frequency.

Common Side Effects: - Bradycardia: heart rate slower than intended. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Nausea.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Visual loss or persistent visual impairment. - QT‑interval prolongation. - Allergic reactions such as rash or angioedema.

Before initiating therapy, clinicians should consider several safety measures.

- Baseline heart rate assessment: ensure resting rate is ≥60 bpm. - Hepatic function: avoid or adjust dose in severe hepatic impairment. - Concomitant bradycardic agents: monitor for excessive slowing of heart rate. - Sick sinus syndrome or atrioventricular block: use with caution or contraindicated. - Strong CYP3A4 inhibitors: avoid co‑administration or adjust therapy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradine interacts with several drug classes that may alter its plasma concentration or additive physiological effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase ivabradine levels. - Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, digoxin): risk of profound bradycardia. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Calcium‑channel blockers verapamil or diltiazem: may modestly raise ivabradine concentrations. - Drugs that prolong the QT interval: monitor ECG for additive prolongation. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may require dose adjustment or enhanced monitoring.